Synarc, Inc. provides medical image-analysis, subject-recruitment, and biochemical-marker services to execute clinical trials for life-science industry clients. The company’s services include protocol design, imaging-site selection and training, imaging equipment monitoring, imaging quality assurance, centralized image analysis, centralized biochemical-marker assays, data management, project management, reporting and medical writing, and regulatory consulting and liaison with global agencies. It offers its services in various therapeutic areas, including cardiology, metabolic disorders, neurovascular diseases, neurology, oncology, orthopedics, osteoarthritis, osteoporosis, and rheumatoid arthritis. Synarc also operates clinical research centers in Europe, China, and Brazil. The company, formerly known as Advanced Imaging Research Services, Inc., was founded in 1998 and is based in San Francisco, California with additional offices in the United States, Denmark, France, Germany, Poland, the Czech Republic, Romania, Lithuania, Estonia, Brazil, Hong Kong, and China.

Sandoz International GmbH engages in the development, production, marketing, and distribution of generic medicines, pharmaceutical and biotechnological active substances, and anti-infectives in Germany and internationally. It offers products for various therapeutic areas, including cardiovascular system, central nervous system, gastrointestinal system, muscle and skeletal system, hormone therapy, and respiratory system. The company’s product portfolio ranges from various application forms, such as oral solids through technologies, including inhalers or injectables to transdermal patches, implants, and biopharmaceutical follow-ons. It sells its products to wholesalers, pharmacies, hospitals, and other healthcare outlets. Sandoz International GmbH was founded in 1886 and is headquartered in Holzkirchen, Germany. The company has research and development, and production sites in Boucherville, Canada; Buenos Aires, Argentina; Cambe and Taboao da Serra, Brazil; Holzkirchen/Rudolstadt and Barleben, Germany; Kolshet, Kalwe, and Mahad, India; Kundl and Schaftenau, Austria; Menges and Ljubljana, Slovenia; Wilson, North Carolina; Broomfield, Colorado; Gebze and Syntex, Turkey; and Strykow, Poland. Sandoz International GmbH operates as a subsidiary of Novartis AG.

Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company develops Zemiva, a molecular imaging pharmaceutical product, which completed Phase II clinical trail for the diagnosis of cardiac ischemia or insufficient blood flow to the heart; and Trofex, a preclinical trail product for the detection of metastatic prostate cancer. Its molecular radiotherapeutic oncology product candidates under development include Azedra that completed Phase I clinical trail for the treatment of pheochromocytoma in adults and neuroblastoma in children; Onalta, a Phase II clinical trail product for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors; and Solazed, a preclinical trail product for the treatment of malignant metastatic melanoma. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003.

Hi-Tech Pharmacal Co., Inc. was founded in 1982 and is based in Amityville, New York. Hi-Tech Pharmacal Co., Inc. (Hi-Tech) is a specialty manufacturer and marketer of prescription, over-the-counter (OTC) and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and OTC brands. It produce a range of products for various disease states, including asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care, neurological disorders, glaucoma and other conditions. The Company’s generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments, as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. On February 27, 2009, the Company purchased substantially all of the assets of E. Claiborne Robins Company, Inc. doing business as, ECR Pharmaceuticals (ECR Pharmaceuticals or ECR).

Herbalife Ltd. (Herbalife) is a global network marketing company that sells weight management, nutritional supplement, energy, sports and fitness products, and personal care products. Herbalife sells its products in 70 countries through a network of over 1.9 million independent distributors. The Company offers science-based products in four principal categories: weight management, targeted nutrition, energy, sports and fitness, and Outer Nutrition. In October 2008, Herbalife announced that it has begun doing business in Honduras, Nicaragua, and Guatemala. These countries become part of the Company's Mexico and Central America region. Five products from Herbalife's nutrition line will be available in each market, including the Company's flagship Formula 1 Nutritional Shake Mix, in four flavors; Performance Protein Powder; Herbal Aloe Drink Concentrate; NRG Tea, and Thermojetics Tea.

Protalex, Inc. company was founded in 1999 and is headquartered in New Hope, Pennsylvania. Protalex, Inc., a development stage company, engages in the development of biopharmaceutical drugs for the treatment of autoimmune and inflammatory diseases in the United States. Protalex company targets the autoimmune diseases rheumatoid arthritis and idiopathic thrombocytopenic purpura. Its lead compound, PRTX-100, is a purified form of the Staphylococcal bacterial protein known as Protein A that has the ability to bind to and to down regulate activation of human B-lymphocytes and macrophages, which are key cells mediating inflammation in certain autoimmune diseases.

China National Pharmaceutical Group (SINOPHARM) is the largest pharmaceutical company in the world's most populous nation. The company researches and develops, manufactures, distributes, and markets medicine and other healthcare products. SINOPHARM manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout the country. It also has 10 subsidiaries and a number of major joint ventures. The company also runs about a dozen retail pharmacy chains. SINOPHARM, which has operations in Africa, France, Germany, Hong Kong, the US, and Vietnam, was formed in 1998. The Chinese government controls the pharmaceutical firm.

Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug candidate tesamorelin is a growth hormone-releasing peptide that Theratechnologies believes can combat a variety of problems, including HIV-related lipodystrophy (the metabolic syndrome characterized by changes in distribution of adipose tissue), muscle wasting associated with chronic obstructive pulmonary disease, sleep maintenance insomnia, and immune dysfunction in elderly patients.

SciClone Pharmaceuticals, Inc. company was founded in 1989 and is headquartered in Foster City, California. SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. SciClone's products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.